# Cell Therapies Core

> **NIH NIH P30** · H. LEE MOFFITT CANCER CTR & RES INST · 2020 · $4,498

## Abstract

PROJECT SUMMARY
The overall goal of the Cell Therapies Core (CTC) is to provide service to members to facilitate translation of
promising therapies for patients with cancer. The CTC manufactures cellular products in support of novel,
investigator-initiated clinical studies, while maintaining compliance with standards set by the U.S. Food and
Drug Administration (FDA) and other accrediting bodies. To accomplish this goal, the CTC's Specific Aims
are to:
 1) Develop new technologies for translation of cellular therapies
 2) Provide regulatory assistance in support of cellular therapies
 3) Educate and train scientists and clinicians committed to careers in cellular therapies
 4) Produce the highest quality cellular products for immunotherapy clinical trials
The CTC works with members through all stages of a clinical trial, including collaboration during pre-clinical
planning. The CTC technical director, manager, and quality staff assist with preparation of protocols,
funding/grant applications, INDs, and other regulatory submissions. Once the cellular therapy agent under
study is administered to the patient, the CTC analytic laboratory may continue to assist in post-treatment
immune monitoring or, when desired by investigators, may directly conduct the immune monitoring studies.
The CTC has four key areas of activity:
 1. New product development, wherein new cell therapy products undergo pre-clinical scale-up, testing,
 and validation
 2. Cell collection and cryostorage to obtain mononuclear cells, lymphocytes, and antigen presenting cells
 for production of cell therapy products and immune monitoring studies
 3. Cell therapy product manufacturing, including dendritic and tumor cell-based gene-modified and un-
 modified vaccines and purification and/or expansion of T lymphocytes (T regulatory cells, tumor
 infiltrating lymphocytes, tumor antigen-associated T cells, chimeric antigen receptor T cells)
 4. An analytic laboratory that performs the dual functions of product quality testing and post-treatment
 immune monitoring
During the project period, the CTC supported 19 cancer center investigators involved in 27 projects and 39
publications. In FY2015, the CTC supported 15 projects, of which 87% represented member projects and 55%
of total usage supported peer-review-funded members.

## Key facts

- **NIH application ID:** 10230148
- **Project number:** 3P30CA076292-22S3
- **Recipient organization:** H. LEE MOFFITT CANCER CTR & RES INST
- **Principal Investigator:** JAMES J. MULE
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,498
- **Award type:** 3
- **Project period:** 1998-02-18 → 2022-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10230148

## Citation

> US National Institutes of Health, RePORTER application 10230148, Cell Therapies Core (3P30CA076292-22S3). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10230148. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*